University Hospital Cologne

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Source

• Not yet recruiting

  IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas

  NCT07888647· Phase 2· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Source

• Not yet recruiting

  Stratification and Treatment in Early Psychosis Study -ASSIST

  NCT07326124· Phase 3· Source

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· Phase 3· Source

• Not yet recruiting

  PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  NCT07877584· Phase 3· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  NCT07825064· Phase 2· Source

• Recruiting

  A study to test a new drug (TRP-001) given before prostate cancer surgery in patients with very high-risk Prostate cancer.”

  2026-526406-32-00· Phase 1· Source

• Not yet recruiting

  Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial

  NCT07840456· Phase 2· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Source

• Not yet recruiting

  A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors

  2024-518348-19-00· Phase 1· Source

• Recruiting

  A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

  NCT07412704· Phase 1/2· Source

• Recruiting

  Stratification and Treatment in Early Psychosis Study - ENHANCE

  NCT06778564· Phase 3· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Source

• Recruiting

  A study of Mirdametinib in Infants and Toddlers under 24months of age with Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PNs)

  2025-522000-24-00· Phase 1· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Source

• Not yet recruiting

  Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair

  NCT07380932· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Source

• Not yet recruiting

  NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  NCT07178730· Phase 3· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  2025-524335-39-00· Phase 3· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Source

• Recruiting

  PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study

  NCT07621003· Source

• Recruiting

  A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes

  2025-524688-19-00· Phase 3· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

  2025-524336-19-00· Phase 3· Source

• Not yet recruiting

  Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients

  NCT06414122· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

  NCT07688213· Phase 2· Source

• Recruiting

  The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?

  2025-524443-12-00· Phase 2· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· Source

• Recruiting

  A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

  NCT07600476· Phase 1· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· Source

• Not yet recruiting

  PHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure

  2026-526261-14-00· Phase 2· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Source

• Recruiting

  PREFer

  NCT06916416· Phase 2· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· Source

• Recruiting

  Pembro-FLASH

  NCT06045159· Phase 2· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  NCT07285655· Phase 3· Source

• Recruiting

  Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support

  NCT07655479· Source

• Recruiting

  A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  NCT07226843· Phase 1· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Source

• Recruiting

  A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

  NCT06792994· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Source

• Recruiting

  Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

  NCT07219459· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers31 recruiting
• Lung cancer29 recruiting
• Chronic lymphocytic leukaemia12 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• HIV9 recruiting
• Liver and biliary tract cancer9 recruiting
• Lupus (SLE)8 recruiting
• Multiple myeloma7 recruiting
• Parkinson disease7 recruiting
• Alzheimer disease5 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Gastric and esophageal cancer5 recruiting
• Heart failure5 recruiting
• Hodgkin lymphoma5 recruiting
• Melanoma5 recruiting
• Metastatic breast cancer5 recruiting
• Ovarian cancer5 recruiting
• Acute myeloid leukemia4 recruiting
• Atrial fibrillation4 recruiting
• Bladder cancer4 recruiting
• Glioblastoma4 recruiting
• Head and neck cancer4 recruiting
• High blood pressure4 recruiting
• Mantle cell lymphoma4 recruiting
• Pancreatic cancer4 recruiting
• Polycystic kidney disease4 recruiting
• Prostate cancer4 recruiting
• Amyloidosis3 recruiting
• Coronary artery disease3 recruiting
• Follicular lymphoma3 recruiting
• Neuroblastoma3 recruiting
• Rheumatoid arthritis3 recruiting
• Sarcoma3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Triple-negative breast cancer3 recruiting
• Chronic myeloid leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Hepatitis B2 recruiting
• Macular degeneration2 recruiting
• Myelodysplastic syndromes2 recruiting
• Schizophrenia2 recruiting
• Sjögren's disease2 recruiting
• Stroke2 recruiting
• Type 2 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Endometrial cancer1 recruiting
• Huntington's disease1 recruiting
• IgA nephropathy1 recruiting
• Long COVID and ME/CFS1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Tuberculosis1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

  NCT07084831· Phase 3· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Source

• Active, not recruiting

  Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)

  2025-521681-10-00· Phase 2· Source

• Active, not recruiting

  Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

  2025-521115-40-00· Phase 2· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· Phase 2· Source

• Not yet recruiting

  Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

  NCT07118449· Phase 2· Source

• Completed

  Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection

  2024-519856-94-00· Phase 2· Source

• Completed

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· Phase 3· Source

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Source

• Completed

  A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

  NCT06560645· Phase 1· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  NCT06624228· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Source

• Completed

  Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)

  2024-511628-16-00· Phase 2· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Source

• Completed

  A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis

  2023-504092-25-00· Phase 2· Source

• Completed

  A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations

  NCT05765734· Phase 1/2· Source

• Completed

  A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).

  NCT05975905· Phase 2· Source

• Active, not recruiting

  A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

  NCT06018337· Phase 3· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Active, not recruiting

  [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

  NCT05870579· Phase 1· Source

• Completed

  Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579· Phase 2· Source

• Active, not recruiting

  Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE

  2022-502105-15-00· Phase 2· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Source

• Completed

  A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting

  2022-502620-49-00· Phase 1· Source

• Completed

  A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

  NCT03779230· Phase 1/2· Source

• Completed

  A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

  NCT04786574· Phase 3· Source

• Active, not recruiting

  Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

  NCT05883644· Phase 3· Source

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Source

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Source

• Completed

  An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

  NCT05848258· Phase 2· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· Phase 3· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· Source

• Completed

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· Phase 3· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Source

• Completed

  Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)

  NCT05429502· Phase 1/2· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Source

• Completed

  A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

  NCT05306574· Phase 3· Source

• Completed

  Phase I study of MGY825 in patients with lung cancer

  NCT05275868· Phase 1· Source

• Active, not recruiting

  Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

  NCT05331183· Phase 3· Source

• Completed

  PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements

  NCT05565794· Phase 2· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Source

• Active, not recruiting

  Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05349214· Phase 3· Source

Trial sites

• University Hospital Cologne1 trial
• 1st Department of Medicine, Cologne University Hospital1 trial
• CF Study Center, University Hospital Cologne1 trial
• Cologne University Hospital1 trial
• Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne0 trials
• Fabry disease center Cologne, Universitätsklinikum Köln1 trial
• Köln Universitätsklinikum1 trial
• Uniklinik Koeln1 trial
• Uniklinik Koeln (Aoer)1 trial
• Uniklinik Koeln - Zentrum fuer Neurologie und Psychiatrie0 trials
• Uniklinik Köln20 trials
• Uniklinik Koln (Aor)2 trials
• Uniklinik Koln /ID# 1459640 trials
• Uniklinik Köln, Institut für Diagnostische und Interventionelle Radiologie1 trial
• Uniklinik Köln (Site 1511)0 trials
• Universitaetsklinikum Koeln17 trials
• Universitaetsklinikum Koeln (AoeR)1 trial
• Universitaetsklinikum Koeln AöR66 trials
• Universitaetsklinikum Koeln, Dermatologie und Venerologie,1 trial
• Universitaetsklinikum Koeln /ID# 1269051 trial
• Universitaetsklinikum Koeln /ID# 1531410 trials
• Universitaetsklinikum Koeln /ID# 1649890 trials
• Universitaetsklinikum Koeln /ID# 1649930 trials
• Universitaetsklinikum Koeln /ID# 2302960 trials
• Universitaetsklinikum Koeln /ID# 2342190 trials
• Universitaetsklinikum Koeln /ID# 2396760 trials
• Universitaetsklinikum Koeln /ID# 2604450 trials
• Universitaetsklinikum Koeln /ID# 2684890 trials
• Universitaetsklinikum Koeln /ID# 2768620 trials
• Universitaetsklinikum Koeln /ID# 2808670 trials
• Universitaetsklinikum Koeln /ID# 2839301 trial
• Universitaetsklinikum Koeln - Innere Medizin I, Onkologie, Haematologie0 trials
• Universitaetsklinikum Koeln - (Recruiting only for part 1B and part 2)1 trial
• Universitaetsklinikum Koeln (Site 0251)1 trial
• Universitaetsklinikum Koeln (Site 0274)1 trial
• Universitaetsklinikum Koeln (Site 0311)1 trial
• Universitaetsklinikum Koeln (Site 0413)0 trials
• Universitaetsklinikum Koeln (Site 0463)1 trial
• Universitaetsklinikum Koeln (Site 0506)0 trials
• Universitaetsklinikum Koeln (Site 0518)0 trials
• Universitaetsklinikum Koeln (Site 0901)1 trial
• Universitaetsklinikum Koeln (Site 1307)0 trials
• Universitaetsklinikum Koeln (Site 1511)1 trial
• Universitaetsklinikum Koeln (Site 2064)1 trial
• Universitaetsklinikum Koeln (Site 2111)1 trial
• Universitaetsklinikum Koeln (Site 4151)0 trials
• Universitaet zu Koeln - Uniklinik Koeln1 trial
• Universitatsklinikum Koeln0 trials
• Universitätsklinikum Köln22 trials
• Universitätsklinikum Köln (AöR)4 trials
• Universitätsklinikum Köln, Centrum für Integrierte Onkologie (CIO)1 trial
• Universitätsklinikum Köln, Centrum für Integrierte Onkologie (CIO) Köln1 trial
• Universitatsklinikum Koln, Innere Medizin I0 trials
• Universitätsklinikum Köln, Institut für Allgemeinmedizin1 trial
• Universitätsklinikum Köln - Kinderkardiologie0 trials
• Universitatsklinikum Koln - University Hospital Cologne0 trials
• University Hospital Cologne25 trials
• University Hospital Cologne AöR258 trials
• University Hospital Cologne AöR, Brustkrebszentrum0 trials
• University Hospital Cologne Department of Neurology1 trial
• University Hospital Cologne /ID# 1660370 trials
• University Hospital Cologne (Koeln) - CF-Studienzentrum0 trials
• University Hospital Cologne (Koeln) - Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin0 trials
• University Hospital Cologne (Universitätsklinikum Köln AöR)0 trials
• University Hospital of Cologne13 trials
• Universitatsklinikum Koln0 trials
• Universitatsklinikum Koln1 trial
• Uniklinik Köln0 trials
• Uniklinik Köln4 trials
• Universitaetsklinikum Koeln2 trials
• Universitätsklinikum Köln4 trials
• University Hospital Cologne1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer95 works · 58 trials
• Parkinson disease70 works · 10 trials
• Hodgkin lymphoma47 works · 15 trials
• Chronic lymphocytic leukaemia26 works · 25 trials
• Glaucoma19 works · 1 trials
• Macular degeneration17 works · 8 trials
• Neuroblastoma17 works · 6 trials
• Diffuse large B-cell lymphoma16 works · 9 trials
• Systemic sclerosis (scleroderma)13 works · 7 trials
• Polycystic kidney disease12 works · 6 trials
• Pulmonary arterial hypertension12 works · 13 trials
• Lewy body dementia10 works · 0 trials
• Spinal muscular atrophy5 works · 0 trials
• Mantle cell lymphoma4 works · 10 trials